...
首页> 外文期刊>Biotechnology and Applied Biochemistry >An automated microscale chromatographic purification of virus-like particles as a strategy for process development
【24h】

An automated microscale chromatographic purification of virus-like particles as a strategy for process development

机译:病毒样颗粒的自动化微型色谱纯化,作为工艺开发的策略

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The development of fermentation processes for recombinant vaccines requires optimizing expression while maintaining high product quality. Changes to cell fermentation conditions are typically evaluated following cell disruption, with expression levels quantified by immunoassay, liquid chromatography or enzyme activity. However, assay titres do not always predict the effects that intracellular aggregation, proteolysis, post-translational modifications and differences in relative impurity levels can have on purification yield and product purity. Furthermore, heterogeneity in the size and surface properties inherent in viral particles makes unit operations such as chromatography less predictable. In these cases, the purification procedure (or a mimic thereof) must be carried out to give accurate information on the impact of changes in fermentation conditions on purification process performance. This was demonstrated for the development of a recombinant vaccine against human papillomavirus produced in Saccharomyces cerevisiae, where the most informative feedback on fermentation variables was obtained by completing a multistep chromatographic purification to evaluate process yield and product purity. To increase the purification throughput and reduce labour, the chromatography was miniaturized 1000-fold from the laboratory scale using microlitre volumes of adsorbent in a pipette tip and automated on a robotic workstation. The microscale purification is shown to be predictive of the laboratory-scale purification in terms of yield and purity, while providing over a 10-fold increase in throughput and allowing for increased monitoring of fermentation processes. In addition, by reducing the volume of cells needed for this assessment, the fermentation can be correspondingly reduced in scale and carried out in parallel for additional throughput gains.
机译:重组疫苗发酵工艺的发展需要优化表达,同时保持高质量的产品。通常在细胞破裂后评估细胞发酵条件的变化,并通过免疫测定,液相色谱法或酶活性定量表达水平。但是,测定滴度并不总是能预测细胞内聚集,蛋白水解,翻译后修饰以及相对杂质水平差异对纯化产率和产物纯度的影响。此外,病毒颗粒固有的尺寸和表面性质的异质性使得诸如色谱之类的单元操作难以预测。在这些情况下,必须执行纯化程序(或其模拟)以提供有关发酵条件变化对纯化过程性能的影响的准确信息。这证明了开发了针对酿酒酵母生产的人乳头瘤病毒的重组疫苗,其中通过完成多步色谱纯化以评估工艺产量和产品纯度,获得了有关发酵变量的最有用的反馈。为了提高纯化通量并减少劳动量,使用移液管吸头中的微升吸附剂将色谱法从实验室规模缩小了1000倍,并在机器人工作站上进行了自动化。微量纯化显示出在产率和纯度方面可预测实验室规模的纯化,同时提供了超过10倍的通量增加并允许增加对发酵过程的监控。另外,通过减少该评估所需的细胞体积,可以相应地减小发酵规模,并并行进行发酵以增加产量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号